2.22
-0.01(-0.45%)
Currency In USD
| Previous Close | 2.23 |
| Open | 2.22 |
| Day High | 2.29 |
| Day Low | 2.18 |
| 52-Week High | 3.07 |
| 52-Week Low | 0.36 |
| Volume | 1.83M |
| Average Volume | 7.31M |
| Market Cap | 294.66M |
| PE | -4.93 |
| EPS | -0.45 |
| Moving Average 50 Days | 1.84 |
| Moving Average 200 Days | 1.07 |
| Change | -0.01 |
If you invested $1000 in Invivyd, Inc. (IVVD) since IPO date, it would be worth $107.12 as of December 04, 2025 at a share price of $2.237. Whereas If you bought $1000 worth of Invivyd, Inc. (IVVD) shares 3 years ago, it would be worth $1,050.05 as of December 04, 2025 at a share price of $2.237.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 12:01 PM GMT
NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 2:35 p.m. ET in M
Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness
GlobeNewswire Inc.
Nov 24, 2025 12:01 PM GMT
VBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from Invivyd’s proprietary antibody discovery technology platformVBY329 meets Invivyd’s target profile of higher pot
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Nov 18, 2025 3:40 AM GMT
NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at an offering price of $2.50 per share and, to certa